Wei Xue, Yang Ming
Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
Front Pharmacol. 2023 Apr 6;14:1180794. doi: 10.3389/fphar.2023.1180794. eCollection 2023.
Breast cancer (BC) is the most prevalent malignant tumor, surpassing lung cancer as the most frequent malignancy in women. Drug resistance, metastasis, and immune escape are the major factors affecting patient survival and represent a huge challenge in BC treatment in clinic. The cell- and subcellular organelle-targeting nanoparticles-mediated targeted BC therapy may be an effective modality for immune evasion, metastasis, and drug resistance. Nanocarriers, efficiently delivering small molecules and macromolecules, are used to target subcellular apparatuses with excellent targeting, controlled delivery, and fewer side effects. This study summarizes and critically analyzes the latest organic nanoparticle-mediated subcellular targeted therapeutic based on chemotherapy, gene therapy, immunotherapy, and combination therapy in detail, and discusses the challenges and opportunities of nanoparticle therapy.
乳腺癌(BC)是最常见的恶性肿瘤,在女性中超过肺癌成为最常见的恶性疾病。耐药性、转移和免疫逃逸是影响患者生存的主要因素,也是临床BC治疗面临的巨大挑战。细胞和亚细胞器靶向纳米颗粒介导的靶向BC治疗可能是一种应对免疫逃逸、转移和耐药性的有效方式。纳米载体能够有效递送小分子和大分子,用于靶向亚细胞结构,具有出色的靶向性、可控递送和较少的副作用。本研究详细总结并批判性分析了基于化疗、基因治疗、免疫治疗和联合治疗的最新有机纳米颗粒介导的亚细胞靶向治疗,并讨论了纳米颗粒治疗面临的挑战和机遇。